Plasma NPY level has been proposed as a biomarker for prostate cancer [241], and a low NPY expression was associated with aggressive grade, higher genomic risk, and shorter metastases-free survival/progression-free survival in prostate cancer [238]. The gene discussed is NPY; the disease is prostate carcinoma.